Clinical Cancer Cells Breakthrough!4 Jan 2024 13:56
Look at the language used by CEO not used lightly in the pharma field …’breakthrough’ ‘transformational’
ANGLE Chief Executive Officer, Andrew Newland, commented:
"Today's breakthrough is the critical next step post the FDA clearance to show in a sample-to-answer format the potential clinical value of NGS molecular analysis on a repeat basis of living cancer cells harvested from patient blood samples. ANGLE is committed to delivering transformational benefits to cancer patients through a simple blood test. This is a major step in this process and I am enormously proud of the ANGLE team in achieving this."